Ads
related to: prostate cancer hormone therapy prognosis options
Search results
Results from the WOW.Com Content Network
Five-year survival rates range from 30–99%, depending on stage. [1] Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA ...
Management of prostate cancer. Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy (prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination.
Androgen deprivation therapy. Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones ...
STAMPEDE (clinical trial) Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Degarelix. Degarelix, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer. [3][5] Testosterone is a male hormone that promotes growth of many prostate tumours and therefore reducing circulating testosterone to very low (castration) levels is often the treatment goal in the management ...
[17] [5] [1] [10] The medication is usually reserved for use in hormone-refractory cases of prostate cancer, although it has been used as a first-line monotherapy as well. [3] Response rates with EMP in prostate cancer are said to be equivalent to conventional high-dose estrogen therapy. [18]
Myth: Testosterone Increases Your Risk of Prostate Cancer "Concerns that testosterone stimulates or promotes cancer growth in men with underlying disease has been pretty controversial," says James ...
Sipuleucel-T is indicated for the treatment of metastatic, asymptomatic or minimally symptomatic, metastatic castrate-resistant hormone-refractory prostate cancer (HRPC). Other names for this stage are metastatic castrate-resistant (mCRPC) and androgen independent (AI) or (AIPC). This stage leads to mCRPC with lymph node involvement and distal ...
Ads
related to: prostate cancer hormone therapy prognosis options